DUBLIN, Dec. 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced two abstracts featuring key data for Ziihera® (zanidatamab-hrii) have been accepted for presentation at the ...
Jazz Pharmaceuticals Plc (NASDAQ: JAZZ) shares are popping on Monday following the company’s positive results of its Phase 3 HERIZON-GEA-01 trial, which assessed Ziihera in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results